share_log

Cantor Fitzgerald Reiterates Overweight on Aclaris Therapeutics, Maintains $38 Price Target

Cantor Fitzgerald Reiterates Overweight on Aclaris Therapeutics, Maintains $38 Price Target

坎托·菲茨杰拉德重申增持 Aclaris Therapeutics,维持38美元的目标股价
Benzinga Real-time News ·  2023/02/07 07:43

Cantor Fitzgerald analyst Louise Chen reiterates Aclaris Therapeutics (NASDAQ:ACRS) with a Overweight and maintains $38 price target.

Cantor Fitzgerald分析师Louise Chen重申Aclaris治疗公司(纳斯达克:ACRS)增持,并维持38美元的目标价。

声明:本内容仅用作提供资讯及教育之目的,不构成对任何特定投资或投资策略的推荐或认可。 更多信息
    抢沙发